WallStreetZenWallStreetZen

NASDAQ: BMRN
Biomarin Pharmaceutical Inc Stock Forecast, Predictions & Price Target

Open Broker Account

Analyst price target for BMRN

Based on 7 analysts offering 12 month price targets for Biomarin Pharmaceutical Inc.
Min Forecast
$70.00-17.42%
Avg Forecast
$111.14+31.11%
Max Forecast
$128.00+51%

Should I buy or sell BMRN stock?

Based on 8 analysts offering ratings for Biomarin Pharmaceutical Inc.
Strong Buy
Strong Buy
4 analysts 50%
Buy
3 analysts 37.5%
Hold
1 analysts 12.5%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their BMRN stock forecasts and price targets.

BMRN stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
Piper Sandler
Bottom 25%
25
Strong BuyMaintains$128.00+51.00%2022-08-09Find out why
Morgan Stanley
Bottom 2%
2
Strong BuyMaintains$117.00+38.02%2022-08-04
SVB Leerink
Bottom 6%
6
BuyMaintains$122.00+43.92%2022-08-04
Barclays
Top 15%
86
Strong BuyMaintains$125.00+47.46%2022-08-04
Cantor Fitzgerald
Bottom 30%
30
Strong BuyInitiates Coverage On$110.00+29.76%2022-07-13
Wedbush
Top 39%
62
HoldAssumes$70.00-17.42%2022-06-13
Credit Suisse
Bottom 3%
3
BuyMaintains$106.00+25.04%2022-06-06
William Blair
Bottom 8%
8
BuyUpgradesN/AN/A2021-11-22

1 of 1

Forecast return on equity

Is BMRN forecast to generate an efficient return?
Company
19.31%
Industry
18.02%
Market
121.74%
BMRN's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is BMRN forecast to generate an efficient return on assets?
Company
14.15%
Industry
13.83%
BMRN is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

BMRN earnings per share forecast

What is BMRN's earnings per share in the next 3 years based on estimates from 9 analysts?
Avg 1 year Forecast
$0.91+213.79%
Avg 2 year Forecast
$2.63+806.9%
Avg 3 year Forecast
$2.81+868.97%
BMRN's earnings are forecast to... subscribe to Premium to read more.
Forecast High Earnings Growth Forecast

BMRN revenue forecast

What is BMRN's revenue in the next 3 years based on estimates from 11 analysts?
Avg 1 year Forecast
$2.1B+10.74%
Avg 2 year Forecast
$2.7B+39.79%
Avg 3 year Forecast
$3.2B+68.71%
BMRN's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

BMRN earnings growth forecast

How is BMRN forecast to perform vs Biotechnology companies and vs the US market?
Company
130.24%
Industry
8.59%
Market
16.88%
BMRN's earnings are forecast to... subscribe to Premium to read more.
Forecast Earnings Growth vs Industry Forecast
BMRN's earnings are forecast to... subscribe to Premium to read more.
Forecast Earnings Growth vs Market Forecast
BMRN's earnings are forecast to... subscribe to Premium to read more.
Forecast Earnings Growth vs Savings Rate Forecast

BMRN revenue growth forecast

How is BMRN forecast to perform vs Biotechnology companies and vs the US market?
Company
19.05%
Industry
24.14%
Market
8.59%
BMRN's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
BMRN's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

BMRN vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
BMRN$84.77$111.14+31.11%Strong Buy
INCY$66.64$84.13+26.24%Hold
BGNE$134.82$299.25+121.96%Strong Buy
ARGX$353.05$408.79+15.79%Strong Buy
TECH$284.00$476.00+67.61%Buy

Biomarin Pharmaceutical Stock Forecast FAQ

Is Biomarin Pharmaceutical Stock a good buy in 2022, according to Wall Street analysts?

The consensus among 8 Wall Street analysts covering (NASDAQ: BMRN) stock is to Strong Buy BMRN stock.

Out of 8 analysts, 4 (50%) are recommending BMRN as a Strong Buy, 3 (37.5%) are recommending BMRN as a Buy, 1 (12.5%) are recommending BMRN as a Hold, 0 (0%) are recommending BMRN as a Sell, and 0 (0%) are recommending BMRN as a Strong Sell.

If you're new to stock investing, here's how to buy Biomarin Pharmaceutical stock.

What is BMRN's earnings growth forecast for 2022-2024?

(NASDAQ: BMRN) Biomarin Pharmaceutical's forecast annual earnings growth rate of 130.24% is forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 8.59%, and and it is also forecast to beat the US market's average forecast earnings growth rate of 16.88%.

Biomarin Pharmaceutical's earnings in 2022 is $54,070,000.On average, 9 Wall Street analysts forecast BMRN's earnings for 2022 to be $168,781,219, with the lowest BMRN earnings forecast at $142,814,878, and the highest BMRN earnings forecast at $189,183,344. On average, 9 Wall Street analysts forecast BMRN's earnings for 2023 to be $487,796,270, with the lowest BMRN earnings forecast at $224,423,379, and the highest BMRN earnings forecast at $688,108,047.

In 2024, BMRN is forecast to generate $521,181,566 in earnings, with the lowest earnings forecast at $489,651,009 and the highest earnings forecast at $552,712,124.

What is BMRN's revenue growth forecast for 2022-2024?

(NASDAQ: BMRN) Biomarin Pharmaceutical's forecast annual revenue growth rate of 19.05% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 24.14%, and while it is forecast to beat the US market's average forecast revenue growth rate of 8.59%.

Biomarin Pharmaceutical's revenue in 2022 is $1,911,709,000.On average, 11 Wall Street analysts forecast BMRN's revenue for 2022 to be $392,642,983,171, with the lowest BMRN revenue forecast at $387,621,834,643, and the highest BMRN revenue forecast at $396,914,075,380. On average, 11 Wall Street analysts forecast BMRN's revenue for 2023 to be $495,653,314,164, with the lowest BMRN revenue forecast at $423,307,006,654, and the highest BMRN revenue forecast at $547,685,781,864.

In 2024, BMRN is forecast to generate $598,200,702,385 in revenue, with the lowest revenue forecast at $467,138,747,325 and the highest revenue forecast at $708,881,119,674.

What is BMRN's forecast return on assets (ROA) for 2022-2025?

(NASDAQ: BMRN) forecast ROA is 14.15%, which is higher than the forecast US Biotechnology industry average of 13.83%.

What is BMRN's Price Target?

According to 7 Wall Street analysts that have issued a 1 year BMRN price target, the average BMRN price target is $111.14, with the highest BMRN stock price forecast at $128.00 and the lowest BMRN stock price forecast at $70.00.

On average, Wall Street analysts predict that Biomarin Pharmaceutical's share price could reach $111.14 by Aug 9, 2023. The average Biomarin Pharmaceutical stock price prediction forecasts a potential upside of 31.11% from the current BMRN share price of $84.77.

What is BMRN's Earnings Per Share (EPS) forecast for 2022-2024?

(NASDAQ: BMRN) Biomarin Pharmaceutical's current Earnings Per Share (EPS) is $0.29. On average, analysts forecast that BMRN's EPS will be $0.91 for 2022, with the lowest EPS forecast at $0.77, and the highest EPS forecast at $1.02. On average, analysts forecast that BMRN's EPS will be $2.63 for 2023, with the lowest EPS forecast at $1.21, and the highest EPS forecast at $3.71. In 2024, BMRN's EPS is forecast to hit $2.81 (min: $2.64, max: $2.98).

What is BMRN's forecast return on equity (ROE) for 2022-2025?

(NASDAQ: BMRN) forecast ROE is 19.31%, which is considered weak.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.